Abstract
Purpose. This was an open-label, dose-escalation trial of intratumoral administration of IL-4 Pseudomonas Exotoxin (NBI-3001) in patients with recurrent malignant glioma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bobo RH, Laske DW, Akbasak A et al (1994) Convectionenhanced delivery of macromolecules in the brain. Proc Nat! Acad Sci USA 91: 2076–2080
Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345: 1008–1012
DeAngelis LM (2001) Brain tumors. N Engl J Med 344: 114–124
Di Massimo AM, Di Loreto M, Pacilli A et al (1997) Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata. Br J Cancer 75: 822–828
Frankel AE, Kreitman RJ, Sausville EA (2000) Targeted toxins. Clin Cancer Res 6: 326–334
Guyotat J, Signorelli F, Frappaz D et al (2000) Is reoperation for recurrence of glioblastoma justified? Oncol Rep 7(4): 899–904
Husain SR, Behari N, Kreitman RJ et al (1998) Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res 58: 3649–3653
Husain SR, Joshi BH, Puri RK (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92: 168–175
Jin W, Bi W, Huang ES et al (1999) Glioblastoma cell-specific expression offibroblast growth factor receptor-1 beta requires an intronic repressor ofRNA splicing. Cancer Res 59: 316–519
Joshi BH, Leland P, Asher A et al (2001) In situ expression of interleukin-4 receptors in human brain tumors and cytotoxicity of a recombinant interleukin-4 (IL-4) cytotoxin in primary glioblastoma cell cultures. Cancer Res 61: 8058–8061
Joshi BH, Plautz GE, Puri RK (2001) Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60: 1168–1172
Kreitman RJ, Puri RK, Pastan I (1994) A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Nat! Acad Sci USA 91: 6889–6893
Kreitman RJ, Puri RK, Pastan I (1995) Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res 55: 3357–3363
Kurpad SN, Zhao XG, Wikstrand CJ et al (1995) Tumor antigens in astrocytic gliomas. Glia 15: 244–256
Laske DW, Ilercil O, Akbasak A et al (1994) Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 80: 520–526
Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3: 1362–1368
LeMaistre CF, Meneghetti C, Howes L et al (1994) Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat 32: 97–103
Lieberman DM, Laske DW, Morrison PF et al (1995) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82: 1021–1029
Liu H, Prayson RA, Estes ML et al (2000) In vivo expression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortex. Cytokine 12: 1656–1661
Puri RK, Hoon DS, Leland P et al (1996) Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 56: 5631–5637
Puri RK, Leland P, Kreitman RJ et al (1994) Human neurological cancer cells Express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 58: 574–581
Puri RK, Leland P, Obiri NI et al (1996) An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. Cell Immunol 171: 80–86
Rahaman SO, Shrama P, Harbor PC et al (2002) Il-13Ralpha2, a decoy receptor for IL-13 acts as an inhibitor ofIL-4-dependent signal transudation in glioblastoma cells. Cancer Res 62: 1103–1109
Rand RW, Kreitman RJ, Patronas N et al (2000) Intratumoral administration of recombinant circularly permuted interleukin4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6: 2157–2165
Surawicz TS et al (1999) Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neurooncology 1: 1990–1994
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag/Wien
About this paper
Cite this paper
Weber, F.W. et al. (2003). Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. In: Westphal, M., Tonn, JC., Ram, Z. (eds) Local Therapies for Glioma Present Status and Future Developments. Acta Neurochirurgica Supplements, vol 88. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6090-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6090-9_15
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-40355-6
Online ISBN: 978-3-7091-6090-9
eBook Packages: Springer Book Archive